View Older Stories
-
BioCryst reports 2025 ORLADEYO revenue of $601 million, up 37%
-
BioCryst raises ORLADEYO drug price by 9% starting January 2026
-
BioCryst Pharma (BCRX) PT Raised to $32 at H.C. Wainwright
-
BioCryst Pharma's (BCRX) Orladeyo Pediatric Approval Will Drive Sales - Citizens
-
TD Cowen Reiterates Buy Rating on BioCryst Pharma (BCRX)
-
BioCryst receives antitrust clearance for Astria acquisition
-
Where can biotech stocks go from here? RBC answers
-
BioCryst presents pediatric HAE data at medical conference
-
BioCryst Pharma (BCRX) PT Lowered to $25 at Citizens After Missing 3Q Sales Consensus
-
Cantor Fitzgerald Reiterates Overweight Rating on BioCryst Pharma (BCRX)
-
BioCryst Pharma (BCRX) Tops Q3 EPS by 11c ; Offers Guidance
-
H.C. Wainwright Reiterates Buy Rating on BioCryst Pharma (BCRX)
-
BioCryst Pharma (BCRX) PT Raised to $26 at Cantor Fitzgerald After Astria (ATXS) Acquisition
-
TD Cowen Resumes BioCryst Pharma (BCRX) at Buy, PT $30
-
BioCryst Pharma (BCRX) PT Raised to $27 at Citizens on Navenibart Deal, Strong HAE Fit
-
Oppenheimer Downgrades Astria Therapeutics (ATXS) to Perform
-
BioCryst Pharma (BCRX) PT Raised to $15 at RBC Capital Amid 10pct Decline
-
BioCryst Pharma (BCRX) PT Raised to $15 at Jefferies
-
BioCryst Pharma (BCRX) Halted, News Pending
-
Evercore ISI Downgrades BioCryst Pharma (BCRX) to In Line
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
BioCryst chief research officer to depart September 1
-
BioCryst Pharma (BCRX) Tops Q2 EPS by 14c ; Offers Guidance
-
RBC Capital on BioCryst Pharma (BCRX): 'We See Shares Undervalued'
-
BioCryst (BCRX) names Babar Ghias as CFO and head of corporate development
-
BioCryst Pharma (BCRX) Announces Sale of European ORLADEYO Business to Neopharmed Gentili for up to $264 Million
-
BioCryst Pharma (BCRX) Presents New Data on the Long-term Efficacy and Safety of ORLADEYO
-
BioCryst Pharma (BCRX): ORLADEYO Approved in Colombia
-
BioCryst Pharma (BCRX) Achieves Reimbursement for ORLADEYO Across all Major European Countries
-
BioCryst Pharma (BCRX) Highlights Real-world Data Showing ORLADEYO Consistently Reduces HAE Attacks Across All Ages
-
BioCryst Pharma (BCRX) Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO
-
BioCryst Pharma (BCRX) PT Raised to $13 at RBC Capital; 'Strong Out of the Gate in 2025'
-
BioCryst Pharma (BCRX) PT Raised to $14 at Jefferies
-
BioCryst Pharma (BCRX) Tops Q1 EPS by 7c ; Offers Guidance
-
BioCryst Pharma (BCRX) Appoints Steve Frank to its Board
-
Cantor Fitzgerald Starts BioCryst Pharma (BCRX) at Overweight
-
Citizens JMP Reiterates Market Outperform Rating on BioCryst Pharma (BCRX)
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
Citizens JMP Reiterates Market Outperform Rating on BioCryst Pharma (BCRX)
-
H.C. Wainwright Reiterates Buy Rating on BioCryst Pharma (BCRX)
-
Citizens JMP Reiterates Market Outperform Rating on BioCryst Pharma (BCRX)
-
Piper Sandler Reiterates Overweight Rating on BioCryst Pharma (BCRX)
-
JPMorgan Reiterates Overweight Rating on BioCryst Pharma (BCRX)
-
BioCryst Pharma (BCRX) Misses Q4 EPS by 6c; offers outlook
-
JMP Securities Reiterates Market Outperform Rating on BioCryst Pharma (BCRX)
-
BioCryst Pharma (BCRX) Launches ORLADEYO in Portugal
-
BioCryst Pharma (BCRX) to Present New ORLADEYO Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
-
BioCryst Pharma (BCRX) 5,200 contracts of January 10 calls trade
-
JMP Securities Reiterates Market Outperform Rating on BioCryst Pharma (BCRX)
-
BioCryst Pharma (BCRX) PT Raised to $12 at Evercore ISI

